Initiated development of a second CAPTN-3 tri-specific antibody targeting TROP2 Manufacturing milestone achieved for IM1240, the first tri-specific 5T4-targeting antibody from the CAPTN-3 platform ...
Zedcor Inc. (TSXV: ZDC) ("Zedcor" or the "Company") is pleased to announce its financial and operating results for the three and nine months ended September 30, 2025. Highlights include:Record ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback